World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
50
Citations
15907
World Ranking
17428
National Ranking
749

Christophe Borg publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Christophe Borg sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 345 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Christophe Borg D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Christophe Borg sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 50 D-Index — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Christophe Borg is affiliated with the Centre Hospitalier Universitaire de Besançon in France. Their research primarily focuses on the field of Medicine, with a significant emphasis on Oncology. Over the course of their career, they have contributed extensively to topics that include Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, and Genetic factors in colorectal cancer.

Their work spans a broad range of subfields such as Oncology, Surgery, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, and Cancer Research. This diverse expertise has been reflected in numerous publications across various well-recognized venues.

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Frontiers in Oncology
  • The Lancet Oncology
  • European Journal of Cancer

Christophe Borg has collaborated frequently with several researchers throughout their career. Notably, they have worked alongside Déwi Vernerey, François Ghiringhelli, Stéfano Kim, Olivier Bouché, and Angélique Vienot.

Their recent papers indicate engagement in multiple large-scale clinical trials and high-impact studies. Examples include:

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial (2021, The Lancet Oncology)
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023, The Lancet Oncology)
  • Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023, The Lancet)
  • Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (2022, Journal of Clinical Oncology)
  • Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study (2020, The Lancet Gastroenterology & Hepatology)

Best Publications

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells

    Zohair Selmani;Abderrahim Naji;Ines Zidi;Benoit Favier

  • Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

    Bernard Escudier;Thierry Dorval;Nathalie Chaput;Fabrice André

  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

    Jaafar Bennouna;Javier Sastre;Dirk Arnold;Pia Österlund

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells

    Fanny Chalmin;Sylvain Ladoire;Grégoire Mignot;Julie Vincent

  • Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

    Erika Vacchelli;Yuting Ma;Elisa E. Baracco;Antonella Sistigu

  • NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs

    Christophe Borg;Abdelali Jalil;Diego Laderach;Kouji Maruyama

  • Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

    Fanny Chalmin;Grégoire Mignot;Mélanie Bruchard;Mélanie Bruchard;Angélique Chevriaux

  • Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

    Christophe Borg;Magali Terme;Julien Taïeb;Cédric Ménard

  • Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

    Boris Guiu;Jean Michel Petit;Franck Bonnetain;Sylvain Ladoire

  • Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

    Cédric Ménard;Jean-Yves Blay;Christophe Borg;Stefan Michiels

  • X-Chromosome Genetics and Human Cancer

    Alain Spatz;Christophe Borg;Jean Feunteun

  • Predictors of responses to immune checkpoint blockade in advanced melanoma.

    N Jacquelot;N Jacquelot;M P Roberti;D P Enot;S Rusakiewicz

  • Role of STAT3 in CD4+CD25+FOXP3+ Regulatory Lymphocyte Generation: Implications in Graft-versus-Host Disease and Antitumor Immunity

    Jean-René Pallandre;Emilie Brillard;Gilles Créhange;Amandine Radlovic

  • Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner

    Takouhie Mgrditchian;Tsolere Arakelian;Jérôme Paggetti;Muhammad Zaeem Noman

  • PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

    Magalie Dosset;Thaiz Rivera Vargas;Thaiz Rivera Vargas;Anaïs Lagrange;Anaïs Lagrange;Romain Boidot;Romain Boidot

  • Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

    Thierry Conroy;Najib Lamfichekh;Pierre-Luc Etienne;Emmanuel Rio

  • PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

    Afag Asgarova;Kamal Asgarov;Yann Godet;Paul Peixoto

  • Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

    Franck Pagès;Thierry André;Julien Taieb;Déwi Vernerey

Frequent Co-Authors

François Ghiringhelli
François Ghiringhelli Centre Georges François Leclerc
Olivier Bouché
Olivier Bouché CHU de Reims
Julien Taieb
Julien Taieb Université Paris Cité
Thierry André
Thierry André Université Paris Cité
Pierre Tiberghien
Pierre Tiberghien University of Franche-Comté
Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
Anne Caignard
Anne Caignard Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Students of Biology and Biochemistry in the USA have a growing range of fully online degree options that support flexible learning and diverse career goals. Whether you’re interested in scientific research, health administration, or wellness, online programs open doors to competitive industries.

For those aiming for leadership roles in healthcare, online doctoral programs healthcare administration provide advanced training in policy, strategy, and management skills. If pharmacy is your focus, programs like an online pharmd can prepare you for clinical and research careers, equipping graduates with the credentials to excel in a changing healthcare landscape.

Fitness and human performance are also natural extensions for biology students. You might consider a fitness degrees online to work in exercise science or coaching, or pursue an online kinesiology bachelor's degree if interested in movement science, rehabilitation, or sports medicine.

Online degrees in these fields are often designed for flexibility, allowing students to balance study with work or family commitments. With innovative curricula and robust career outcomes, these pathways enable biology and biochemistry graduates to broaden their professional opportunities.

Best Scientists Citing Christophe Borg

Trending Scientists

Recently Published Articles